GlassScriptPhysician profile
Henry Shugart
NPI 1134195126
$2,117.23
in general payments reported to CMS, 2019-2025
22 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $135 · 2021: $112 · 2022: $548 · 2023: $673 · 2024: $215 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.63 | 2022-2025 | Vraylar, Ubrelvy, Linzess |
| Intuity Medical INC | $375.84 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Dexcom, INC. | $271.58 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $198.04 | 2019-2025 | |
| Senseonics, Incorporated | $177.00 | 2019-2020 | |
| Amgen INC. | $89.35 | 2019-2023 | Prolia, Evenity |
| Astellas Pharma US INC | $83.63 | 2019-2025 | Veozah |
| Abbott Laboratories | $62.38 | 2021-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $54.13 | 2020-2022 | |
| Ascensia Diabetes Care US INC. | $40.82 | 2024 | |
| Insulet Corporation | $36.55 | 2024 | Omnipod |
| Zyla Life Sciences, INC. | $28.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.41 | 2020 | |
| Allergan, INC. | $24.21 | 2020 | |
| Sumitomo Pharma America, INC. | $23.00 | 2024 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $20.78 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biohaven Pharmaceuticals, INC. | $20.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.04 | 2022 | |
| Esperion Therapeutics, INC. | $17.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.97 | 2022 | |
| Glaxosmithkline, LLC. | $12.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Shugart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.